NASDAQ:TCDA

Tricida - TCDA Stock Forecast, Price & News

$0.23

0.00 (-1.63%)

(As of 12/8/2022 02:22 PM ET)

Add

Compare

Today's Range: $0.23
▼
$0.26
50-Day Range: $0.19
▼
$12.49
52-Week Range: $0.19
▼
$13.85

Volume: 305,253 shs
Average Volume: 14.01 million shs
Market Capitalization: $13.07 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Tricida MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 7,033.9% Upside
$17.00 Price Target
Short Interest: Bearish
46.86% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.97
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$13.74 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.88) to ($1.01) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

600th out of 1,027 stocks

Pharmaceutical Preparations Industry

280th out of 503 stocks

3.0

Analyst's Opinion

Consensus Rating
Tricida has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Tricida has a forecasted upside of 7,033.9% from its current price of $0.24.
Amount of Analyst Coverage
Tricida has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
46.86% of the float of Tricida has been sold short.
Short Interest Ratio / Days to Cover
Tricida has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Tricida has recently increased by 10.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Tricida does not currently pay a dividend.
Dividend Growth
Tricida does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Tricida has received a 72.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.
Environmental Sustainability
The Environmental Impact score for Tricida is -0.97.

1.4

News and Social Media Coverage

News Sentiment
Tricida has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
Search Interest
Only 48 people have searched for TCDA on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.
MarketBeat Follows
Only 17 people have added Tricida to their MarketBeat watchlist in the last 30 days. This is a decrease of -35% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Tricida insiders have bought 98.02% more of their company's stock than they have sold. Specifically, they have bought $13,737,531.00 in company stock and sold $6,937,442.00 in company stock.
Percentage Held by Insiders
35.60% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Tricida are expected to grow in the coming year, from ($1.88) to ($1.01) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Tricida is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Tricida is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Tricida (NASDAQ:TCDA) Stock

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Stock News Headlines

November 15, 2022 | finance.yahoo.com

Tricida Announces Third Quarter 2022 Financial Results

November 2, 2022 | finance.yahoo.com

Tricida Provides Strategic Update

December 8, 2022 | Investing Trends (Ad)

"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race

Did you know each electric car battery requires 220 pounds of graphite – more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution.

October 25, 2022 | markets.businessinsider.com

Why Tricida Stock Is Tanking Today

October 25, 2022 | bizjournals.com

Failed trial sends Peninsula kidney drug company's stock tumbling 94%

October 25, 2022 | msn.com

This Biotech Lost 95% in a Single Day. It Still Deserves Credit

October 25, 2022 | finance.yahoo.com

Tricida Shares Nosedive After Disappointing Data From Much Anticipated Kidney Disease Trial

October 24, 2022 | investorplace.com

Why Is Tricida (TCDA) Stock Down 90% Today?

December 8, 2022 | PressReach (Ad)

Top Innovation Stock

Today's stock market report features an AI Robotics tech stock with a $4 million order backlog.

October 24, 2022 | finance.yahoo.com

Tricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of Veverimer

October 19, 2022 | seekingalpha.com

Tricida announces $125M debt facility - Seeking Alpha

October 19, 2022 | seekingalpha.com

Tricida enters $125M debt facility (NASDAQ:TCDA) - Seeking Alpha

October 19, 2022 | benzinga.com

Tricida Whale Trades For October 19 - Tricida (NASDAQ:TCDA) - Benzinga

October 19, 2022 | businesswire.com

Tricida Announces $125 Million Debt Facility with Hercules Capital - Business Wire

October 18, 2022 | benzinga.com

$2 Million Bet On Tricida? 3 Stocks Insiders Are Buying - Tricida (NASDAQ:TCDA), Riley Exploration Permia - Benzinga

October 14, 2022 | businesswire.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm - Business Wire

October 13, 2022 | benzinga.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Te - Benzinga

October 7, 2022 | benzinga.com

Tricida Whale Trades Spotted

October 4, 2022 | uk.investing.com

$17 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UK

October 3, 2022 | finance.yahoo.com

Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022

October 3, 2022 | businesswire.com

Tricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022 - Business Wire

September 29, 2022 | uk.investing.com

Over $352 Million Bet On Occidental Petroleum? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UK

September 27, 2022 | benzinga.com

6TCDA : Tricida Whale Trades Spotted

September 24, 2022 | benzinga.com

TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to - Benzinga

September 21, 2022 | seekingalpha.com

Tricida: Important Binary Event Coming Up (NASDAQ:TCDA) - Seeking Alpha

September 9, 2022 | benzinga.com

Tricida (NASDAQ:TCDA) – TRICIDIA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick - Benzinga

September 8, 2022 | benzinga.com

Tricida (NASDAQ:TCDA) – Tricida 10% Owner Makes $7.92M Stock Purchase - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

TCDA Company Calendar

Last Earnings: 11/14/2022
Today: 12/08/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 4/04/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TCDA
CUSIP: N/A
CIK: 1595585
Web: www.tricida.com
Phone: (415) 429-7800
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.00
High Stock Price Forecast: $18.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +7,143.3%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-176,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -103.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.87
Quick Ratio: 4.87

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 55,670,000
Free Float: 35,851,000
Market Cap: $13.07 million
Optionable: Not Optionable
Beta: 0.08

Key Executives

Dr. Gerrit Klaerner Ph.D. (Age 50)
Founder, Pres, CEO & Exec. Director
Comp: $992.55k

Mr. Geoffrey M. Parker (Age 57)
COO, CFO & Exec. VP
Comp: $656.28k

Mr. Robert L. McKague J.D.
Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer

Dr. Dawn Parsell Ph.D. (Age 60)
Exec. VP of Clinical Devel.
Comp: $649.17k

Ms. Annie Yoshiyama (Age 39)
VP of Fin. & Chief Accounting Officer

Jackie Cossmon
VP of Investor Relations & Communications

Mr. Edward J. Hejlek Esq. (Age 66)
J.D., Exec. VP of Intellectual Property

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TCDA Stock - Frequently Asked Questions

Should I buy or sell Tricida stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View TCDA analyst ratings or view top-rated stocks.
What is Tricida's stock price forecast for 2023?: 5 equities research analysts have issued 12-month price objectives for Tricida's stock. Their TCDA share price forecasts range from $16.00 to $18.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 7,079.1% from the stock's current price.
View analysts price targets for TCDA or view top-rated stocks among Wall Street analysts.
How have TCDA shares performed in 2022?: Tricida's stock was trading at $9.56 at the beginning of 2022. Since then, TCDA stock has decreased by 97.5% and is now trading at $0.2368.
View the best growth stocks for 2022 here.
When is Tricida's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our TCDA earnings forecast.
How were Tricida's earnings last quarter?: Tricida, Inc. (NASDAQ:TCDA) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.10.
What is Gerrit Klaerner's approval rating as Tricida's CEO?: 2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).
When did Tricida IPO?: (TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.
What is Tricida's stock symbol?: Tricida trades on the NASDAQ under the ticker symbol "TCDA."
Who are Tricida's major shareholders?: Tricida's stock is owned by many different institutional and retail investors. Top institutional shareholders include VR Adviser LLC (16.26%), BlackRock Inc. (6.64%), Commodore Capital LP (3.55%), Vanguard Group Inc. (2.99%), Citadel Advisors LLC (0.00%) and Point72 Asset Management L.P. (0.00%). Insiders that own company stock include Brian M Isern, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Orbimed Advisors Llc, Robert J Alpern, Robert Mckague, Sandra I Coufal, Venrock Healthcare Capital Par and Wilhelm Stahl.
View institutional ownership trends.
How do I buy shares of Tricida?: Shares of TCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Tricida's stock price today?: One share of TCDA stock can currently be purchased for approximately $0.24.
How much money does Tricida make?: Tricida (NASDAQ:TCDA) has a market capitalization of $13.18 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis.
How can I contact Tricida?: Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com.

This page (NASDAQ:TCDA) was last updated on 12/8/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial